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ABSTRACT
Objective: To evaluate the cost-effectiveness of microwave endometrial
ablation (MEA) and thermal balloon endometrial ablation (TBALL) for
heavy menstrual bleeding.
Methods: A cost-utility analysis performed alongside a pragmatic RCT in
a single hospital within Scotland on women undergoing MEA and TBALL.
Resource use data collected from all 314 trial participants were combined
with study speciﬁc and published unit cost data to estimate a cost per
patient. Quality-adjusted life-years (QALYs) were based on EQ-5D
responses at baseline, 2 weeks, 6 and 12 months. The incremental cost per
QALY of TBALL versus MEA was calculated and bootstrapping was
performed to determine the likelihood that a treatment would be cost-
effective at different threshold values for society’s willingness to pay for a
QALY.
Results: The mean cost of TBALL (10 years equipment life, 100 uses
annually) of reusable equipment was £181 (95% conﬁdence interval [CI]
£70–434) greater than MEA. There were no statistically signiﬁcant differ-
ences between the total nonhealth costs and health beneﬁts of the two
arms. On average, MEA provided more QALYs after adjusting for baseline
EQ-5D score (0.017; 95% CI 0.017–0.051). In terms of mean incremental
cost per QALY, MEA was, on average, dominant (less costly and at least
as effective) and there was over a 90% chance that MEA would be
considered cost-effective at a £20,000 threshold of a cost per QALY.
Conclusions: MEA is likely to be more cost-effective than TBALL at
1 year. Further longer-term follow-up is, however, needed.
Keywords: cost-utility analysis, health-related quality of life, quality-
adjusted life-year, randomized controlled trial.
Introduction
Women with heavy menstrual bleeding represent a signiﬁcant
proportion of gynecology referral with 1 in 20 women in the
United Kingdom aged 30 to 49 years consulting their general
practitioners each year [1]. Endometrial ablation has been clearly
established as an alternative to hysterectomy [2]. Second-
generation techniques are easier to learn and undertake than the
ﬁrst-generation techniques, whereas other beneﬁts include speed
of the procedure, ability to perform them under local anesthetic,
and for “many techniques,” no requirement for endometrial
thinning agents such as GnRh analogues [3–5]. It is essential that
costs are established for new technologies in addition to effec-
tiveness to inform health-care purchasers of the most efﬁcient
technologies. In this article, we report a cost-utility analysis,
undertaken as part of a randomized controlled trial (RCT), com-
paring two widely used second-generation techniques, micro-
wave endometrial ablation (MEA) (Microsulis Medical Ltd.,
Denmead, Hampshire, UK) and Thermal Balloon endometrial
ablation (TBALL) (Thermachoice III, Ethicon Ltd., Livingston,
West Lothian, UK).
Methods
Full details of the trial design and clinical outcomes have been
published elsewhere [6]. In summary, a prospective RCT was
performed enrolling 320 women complaining of heavy menstrual
bleeding and assessed as suitable for endometrial ablation.
Women were recruited to the trial from either a general gynecol-
ogy clinic or a dedicated menstrual disorders clinic between
January 2003 and January 2005. Women were randomized to
either MEA or TBALL under local or general anesthesia depend-
ing on patient preference. Patients were eligible if they were
premenopausal, had a uterine size equivalent to a 12-week preg-
nancy or less with no histopathological abnormalities of the
endometrium, had completed their families, and had no ﬁbroids
obstructing the uterine cavity. They gave informed consent to
participate in the trial. Randomization to the trial groups was
performed by a fully automated telephone randomization
system. The randomization system allowed treatment allocation
to be computer-generated using permuted blocks. The patients
were not informed of their treatment and the data were entered
and analyzed independently by researchers who were unaware of
the treatment allocation.
Baseline characteristics and clinical results of the randomized
trial have been reported elsewhere [6]. Three hundred twenty
patients were recruited into the study and there were six post-
randomization exclusions (four withdrew consent and two were
unsuitable for treatment). The sample size calculation was deter-
mined by a clinical end point as reported elsewhere [6] and not
on costs or quality-adjusted life-years (QALYs). The economic
analysis was conducted alongside the RCT and was based on an
intention to treat basis and includes 314 women within the RCT.
Measurement of Costs
Estimation of NHS resource use and costs. The costs before the
operation were assumed to be similar for both groups and that
the differences between the procedures related to the cost of
surgery itself and the costs of subsequent management. Data on
resource use were collected by staff-completed report forms from
the time of hospital admission to discharge. Patient-completed
questionnaires additionally assessed resource use from admission
to discharge, at 2 weeks, 6 and 12 months following the proce-
dure. The former included resource use in theater, in patient stay,
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and any postoperative complications. Theater resource use
included the staff present (in the operating theater, anesthetic
room, and recovery area); consumables (in theater and the anes-
thetic room); and drug usage (i.e., anesthetics and analgesia).
Total hospital stay was obtained for each woman. Postopera-
tive resource use related to the management of complications,
e.g., infections, postoperative analgesia. Two-week, 6- and
12-month patient questionnaires provided data on additional
surgical procedures, use of medication, readmissions, number of
visits to the general practitioner, and outpatient attendance since
discharge following the procedure. Table 1 describes the main
elements of resource used in the trial and their unit costs where
applicable. All costs were derived using unit costs for 2006 UK £
Sterling.
The total costs of theater comprised of the equipment and
theater supplies such as consumables of both local and general
anesthesia (D & C trays, surgical gloves among others) and
overhead costs, theater time costs, and staff time costs. Scottish
health service data were used to estimate the overhead costs [11].
The costs of the MicrosulisM machine and Thermachoice genera-
tor and catheters were based on personal communication with
the manufacturers and based upon the public list price. An alter-
native source of cost data would be to use a rental price; however,
such data are typically subject to various sorts of deals and
negotiations, which means that they are not good proxies for the
economic cost of the resources [12]. The outright purchase cost
for TBALL equipment was £2585 and the MEA equipment was
£50,000. Although the costs of equipment especially for MEA
were substantial, equipment can be used for many patients and
over a prolonged period of time; therefore, the cost assigned to
each patient is more modest. These costs were converted into an
equivalent annual costs by using the UK recommended discount
rate of 3.5% [13] and assuming that the equipment would last
10 years. The cost per patient was estimated by dividing the
equivalent annual cost by the estimated annual use (100 proce-
dures per year in the base-case analysis) of the reusable equip-
ment. Table 2 shows how the reusable equipment cost per patient
for both operations was calculated.
The average equipment cost per patient for TBALL was based
on the summation of the cost per patient of reusable equipment,
the cost of disposable catheters, and the charge per patient for the
umbilical cable. For MEA, the equipment cost per patient was
based on the cost per patient of reusable equipment, the cost of
the probe, and a cost per patient for maintenance and for pro-
cessing of reusable equipment where relevant. The costs of other
items, e.g., medicines used for each patient, were based on pur-
chase costs and were relevant published estimates or manufac-
turers list prices.
The costs of the staff involved were based on the average
national wages for each relevant scale for medical and nursing
staff combined with the duration of the operation. The overhead
costs per minute of use for the theater, treatment room, and the
day surgery ward were likewise combined with duration that
they were used. Following discharge, the cost of any follow-up
visits or tests performed were based upon the type of visit made,
e.g., to the GP or outpatient department and type of tests
performed.
Mean costs for both MEA and TBALL were derived for each
area of resource use (e.g., operation costs, cost of secondary care,
etc.) (Table 3). These costs were then summed to derive mean
total costs estimates for each intervention and incremental costs
estimated.
Estimation of women’s resource use and costs. Women’s
resource use was deﬁned as time taken to attend GP, outpatient
or inpatient appointments, travel costs, and the time taken off
usual activities to attend these appointments. Similar costs were
also included for spouses, relatives, or friends that accompanied
the women to their appointments. This information was col-
lected through postal questionnaires to the women administered
Table 1 Resource use unit cost
Variables Resource use unit Average unit cost
Theater
Specialist registrar Minute [7] £0.49
Nurse—Grade G Minute [7] £0.39
Nurse—Grade D Minute [7] £0.23
Nurse—Grade A Minute [7] £0.14
Operating department assistant ODA—MT02 Minute [7] £0.28
Consultant anesthetist Minute [7] £0.52
Equipment
Hysteroscope Per woman £2.32
MEA
Microsulis machine and probe Per woman* £252.99
TBALL
Thermachoice generator and disposable catheter Per woman* £346.41
Local anesthesia Per procedure† £15.10
General anesthesia Per procedure† £16.47
Overhead costs
Day surgery theater Minute [8] £0.055
Treatment room Minute [8] £0.009
Day surgery ward Minute [8] £0.008
Other NHS resource use
Inpatient stay Per night £54.80
GP consultations Per surgery consultation [7] £25
Medications prescribed Cost of actual medicine [9] Various
Outpatient appointments Cost per patient [8] £101
Investigations (radiology, microbiology) Cost per patient [10] Various
*Estimates of costs of equipment and relevant consumables were based on personal communication with the Grampian area sales representatives for Microsulis and Johnson and Johnson Medical
companies.
†Estimates were based on consumables for local and general anesthesia such as D & C tray, surgical gloves, cusco vaginal speculum, theater greens, perennial towel, etc.
MEA, microwave endometrial ablation;TBALL, thermal balloon endometrial ablation.
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at 2 weeks, 6 and 12 months. Travel costs to women and their
families were generated using actual fares when public transport
was used and published mileage rates for those that used their
own vehicles [14]. Travel time and time spent in hospital was also
recorded. For women who would have been engaged in
employed work, the value of their time was taken as the gross
average full-time rate for women [15]. The value for those
women who normally did housework and looked after children
was based on 57% of the average national rate and 43% for
those who may have been involved in leisure activities [16]. Cost
of friends/relatives accompanying women to hospitals was esti-
mated in the same way.
Derivation of QALYs
The health outcomes of the economic evaluation were expressed
in terms of QALYs; QALYs have been used in order to reﬂect the
effect of the treatment on an individual’s health-related quality of
life. QALYs were estimated from the participant’s responses to
the EQ-5D questionnaire collected at baseline, 2 weeks, 6 and
12 months. The EQ-5D [17] is a generic measure of health status
that deﬁnes health in terms of ﬁve dimensions: mobility, self-care,
usual activities, pain or discomfort, and anxiety or depression.
Each of these dimensions has three levels: no, moderate, or
extreme problems. The combinations of these dimensions and
levels provide 243 possible health states. The responses of par-
ticipants were converted into utilities using a tariff scale derived
from a sample of UK general public [18]. This approach used to
generate QALYs has been extensively validated and has been
recommended for decision-making by NICE [13]. The difference
in QALY score was derived using an analysis of covariance to
control for baseline EQ-5D scores. Approximately 25% of par-
ticipants had one or more missing EQ-5D scores. Table 4 pro-
vides details of the number of women providing the EQ-5D
responses at each time point. This data was assumed to be
missing completely at random, i.e., that the probability that an
observation (Xi) is missing is unrelated to the value of Xi or to the
value of any other variables. Differences between groups were
assessed using the multiple regression adjusted for baseline.
Assessment of Cost-Effectiveness
The perspective of the cost-effectiveness analysis was the NHS as
recommend by NICE in their reference case [13]. Patient costs
were, however, included to provide additional information that
may be useful for readers who may want to consider a slightly
wider perspective. These costs were not used in the estimation of
cost-effectiveness estimates. All data analyses were performed
using Stata/SE10 (StataCorp LP). Mean differences were then
estimated for each area of resource use, and (as is standard with
the analysis of cost data) nonparametric bootstrapping (using
1000 iterations) was used to estimate conﬁdence intervals around
the difference in the mean total cost, and mean QALYs [19]. The
conﬁdence intervals were estimated using normal-based 95%
conﬁdence intervals. Using the estimates of incremental cost and
QALYs, the incremental cost per QALY ratio (ICER) was esti-
mated to assess the likelihood of the intervention, being more
cost-effective. Decisions about the acceptability of a technology
as an effective use of NHS resources were based primarily on the
cost-effectiveness estimate of below an ICER of £20,000 per
QALY [13]. No discounting, other than to take into account the
lifespan of reusable equipment, was performed, as the time
horizon was only 1 year. The data analysis was based on inten-
tion to treat.
Sensitivity Analysis
Sensitivity analysis is necessary to assess how robust conclusions
are and identify areas where research is needed [20]. The vari-
Table 2 Cost of reusable equipment
Equipment Price Life (years) Disc factor Equivalent annual cost Cost per patient
MEA Microsulis* £50,000.00 10 0.120 £6,010.00 £60.10
TBALL Thermachoice III* £2,585.00 10 0.120 £310.72 £3.11
Equipment used for both procedures
Lens £2,793.00 5 0.237 £663.06 £1.11
Sheath £353.00 5 0.237 £83.80 £0.14
Light guide £471.00 5 0.237 £111.82 £0.19
Basket for lens £191.00 5 0.237 £45.34 £0.08
Processing costs £0.81 £0.81 £0.81
Total cost of equipment used for both procedures £2.32
Note: Cost per patient for MEA andTBALL equipment was based on 100 patients using the equipment each year. For equipment used for both interventions, it was assumed that 600 patients
use these equipment each year as the equipment is used for other procedures.
*Estimates of costs of equipment and relevant consumables were based on personal communication with the Grampian area sales representatives for Microsulis and Johnson and Johnson Medical
companies.
MEA, microwave endometrial ablation;TBALL, thermal balloon endometrial ablation.
Table 3 NHS and nonhealth mean cost per patient
Area of resource use TBALL (£) MEA (£) Difference (£)
Cost Cost Cost
Operation costs Theatre equipment and staff £516.89{531.07} £418.29{437.35} £98.60 (95% CI 83.25, 113.95)
Primary and secondary service care GP, outpatient and inpatient visits £238.17{50} £92.66{50} £145.51 (95% CI -105.72, 396.74)
Total NHS costs* £758.46{583.71} £576{550.03} £181 (95% CI -70.24, 433.88)
Patient and companion Travel time and cost of travel 0.25{0} £0.56{0} £-0.32 (95% CI -0.97, 0.33)
Patient and companion Time off work £462.78{205.22} £488.43{360.03} £-25.65 (95% CI -292.14, 240.85)
Total patient and companion costs* £333.35{163.65} £494.27{360.03} £-160.92 (95% CI -375.92, 54.07)
{ } Median; CI (conﬁdence interval):The conﬁdence intervals are normal-based 95% conﬁdence intervals.
*The totals may not be the summation of the values as the number of women contributing data at each time point differs, whereas the total values are based on women with complete data.
MEA, microwave endometrial ablation;TBALL, thermal balloon endometrial ablation.
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ables that were considered uncertain in this study related to the
cost of the different services used. One-way sensitivity analysis
was conducted using plausible variations in the cost of the equip-
ment used for the procedures. Base-case total costs were gener-
ated based on the assumption that the equipment had a lifespan
of 10 years and that 100 procedures were performed annually.
This assumption was relaxed in the sensitivity analysis by varying
the number of procedures carried out to 250 and 50 and chang-
ing the lifespan of the equipment from 10 to 5 years. As
described below, other one-way sensitivity analyses were per-
formed using different costs and quality-of-life data.
The cost of the MEA equipment can be based on two different
systems of supply. One is the outright purchase of equipment and
the other is a placement arrangement fee with a speciﬁed list
price. To maximize the generalizability of the results, sensitivity
analysis was performed using the arrangement fee used in the
majority of UK centers.
The total costs per patient were highly skewed with a small
number of women (four in TBALL arm one in MEA) having
much higher costs because they had each received a hysterec-
tomy. Further sensitivity analysis was also performed excluding
these high service user patients. As base-case analysis assumed
that missing data were completely missing at random, sensitivity
analysis was also performed using imputed EQ-5D data. Imputed
values were estimated by carrying forward the last reported
EQ-5D value. Sensitivity analysis was also performed using all
available cost data.
Results
The results of baseline data, the characteristics of women, and
the clinical outcomes are reported in detail elsewhere [6].
NHS Costs
A summary of the mean cost per woman of the two interventions
is presented in Table 3. This table summarizes costs and shows
that the main determinant of incremental cost was the cost of the
equipment used in the procedures and the increased care pro-
vided to people in the TBALL arm between 6 and 12 months.
The mean operation cost (which includes staff, equipment, over-
head, and consumables) was £418 for MEA (median £437) and
£517 for TBALL (median £531). On average, TBALL was asso-
ciated with a mean additional operation cost of £99 (95% CI £83
to £114). The mean total cost per patient in the MEA arm was
£577 (median £550), and in the TBALL arm, £758 (median
£584). TBALL was, on average, more costly by £181 (95% CI
£70–434).
Nonhealth Service Costs
Table 3 also reports mean nonhealth cost per woman. The mean
total travel time cost was £0.57 for the MEA arm (median £0.30)
and £0.24 for the TBALL arm (median £0.14). The mean total
cost for time taken off usual activities such as employed work
was £488 for the MEA arm (median £360) and £463 for the
TBALL arm (median £205). On average, patient travel and time
off work costs were £160 (95% CI £-54 to £375) greater for
MEA than TBALL. There was no statistically signiﬁcant differ-
ence in total nonhealth costs of the two arms
QALYs
Table 4 reports the EQ-5D scores for each arm of the trial at
baseline, 2 weeks, 6 and 12 months. Also reported are the dif-
ferences between arms in EQ-5D score. From these data, it was
estimated that the mean QALYs were 0.87 (median 0.92) for the
MEA arm and 0.86 (median 0.93) for the TBALL arm. The mean
difference in QALYs after adjusting for baseline EQ-5D score
was 0.017 (95% CI -0.017 to 0.051), i.e., the MEA arm was
associated with more QALYs, although the difference was not
statistically signiﬁcant
Estimation of Cost-Effectiveness
The cost-effectiveness acceptability curve generated from the dis-
tribution of bootstrapped ICERs indicated that there is a 93%
chance that MEA is more cost-effective than TBALL given the
£20,000 threshold of a cost per QALY value (Fig. 1). The results
show that if the decision-maker is willing to pay £50,000, MEA
still has an 89% probability of being cost-effective. This greater
chance of MEA being considered cost-effective was mainly driven
by a difference in beneﬁts rather than costs (in 85% of bootstrap
replications, MEA provided greater QALYs than TBALL).
Sensitivity Analysis
Sensitivity analysis relaxing the base-case analysis assumptions of
the life span of the equipment as well as number of procedures
performed did not materially change the results. However, the
probability of society’s willingness to pay for an additional
QALY reduced to 74% when the cost of MEA equipment was
based on 50 procedures and a 5-year life span (Table 5). When
the equipment cost of MEA was based on the arrangement that
most hospitals in the United Kingdom have, the mean total cost
per patient in the MEA arm was £702 (median £550) and
TBALL was, on average, more costly by £55 (95% CI £185 to
£297). In the other one-way sensitivity analysis where the
average price of TBALL disposable catheters was increased to the
maximum manufacturer list price (£390), TBALL was more
costly on average than MEA. The results based on total costs
derived using the available data (both from participants for
whom complete and incomplete data were available) were not
sensitive to any of the changes around the derivation of costs.
Table 4 EQ-5D scores
EQ-5D MEA (n = 153) TBALL (n = 154) Difference* CI* P-value*
Baseline 0.77 (0.23) 0.77 (0.28)
n = 147† n = 140†
2 weeks 0.87 (0.16) 0.87 (0.18) 0.008
n = 141† n = 137†
6 months 0.88 (0.17) 0.86 (0.21) 0.023
n = 141† n = 135†
12 months 0.84 (0.24) 0.82 (0.26) 0.019
n = 128† n = 124†
Adjusted QALYs 0.87 (0.15) 0.86 (0.17) 0.017 -0.017 to 0.051 0.331
*Adjusted for baseline EQ-5D scores.
†Number of women contributing data at each time point (Standard deviations).
MEA, microwave endometrial ablation; QALY, quality-adjusted life-year;TBALL, thermal balloon endometrial ablation.
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The results of analysis using imputed missing EQ-5D data also
did not change the results. When the high-cost women were
excluded (four from TBall; one from MEA), the difference in
total costs reduced to £94 (95% CI £67 to £121) from £181.
However the cost-effectiveness conclusions did not change.
Discussion
Although the comparison of the point estimates did not show a
statistically clear-cut difference between the groups, the results of
the bootstrapping exercise suggested that MEA is likely to be
considered cost-effective. The mean QALY scores for the two
procedures (0.86 for TBALL and 0.87 for MEA) are similar to
those reported elsewhere [21]. Garside and colleagues, for
example, also found that the differences were slight, and as a
consequence, it appears that the second-generation ablation
methods result in similar quality of life. However, it is necessary
to view these results bearing in mind that these data are based on
a maximum 1-year follow-up and it does not take into the
long-term failure rates of both treatments. Agencies such as
NICE need to consider this study and evidence for other inter-
ventions when drawing conclusions as to which treatment is
cost-effective in this patient population. This study is the ﬁrst
head-to-head economic comparison of second-generation abla-
tion techniques, and therefore, it forms an important part of this
evidence base. The QALY scores were generated using EQ-5D
scores and they were slightly higher than those reported in a
study by Sculpher (1998), who generated QALY scores using the
time trade-off valuation technique [22]. With both methods,
there are problems eliciting values for chronic health states that
may affect quality of life on a daily basis, but for which, the worst
effects occur during acute episodes. There are also some ques-
tions as to whether the EQ-5D is sensitive enough to capture the
loss in quality of life for this group of women [23,24].
The results of the bootstrapping exercise in the base-case
analysis suggest that there is a 93% chance that MEA is less
costly than TBALL. The primary cause for this is increased cost
of the operation for TBALL compared with MEA and cost of
care provided in the follow-up period. The increased cost of the
operation was mainly driven by the duration of the procedure
and the cost of the equipment. The TBALL operation was, on
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Figure 1 (a) Cost-effectiveness plane microwave
endometrial ablation (MEA) versus thermal balloon
endometrial ablation (TBALL); (b) Cost-
effectiveness acceptability curve for MEA versus
TBALL.
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importantly, the equipment costs associated with TBALL were
considerably higher than those for MEA. Within our analysis, it
was assumed that there was an outright purchase of the equip-
ment. These differed from the published data [21] whose baseline
cost for TBALL was less than that of MEA. In practical terms,
there are two different supply systems for the MEA equipment:
one is the direct purchase of the equipment and the other is based
on a placement arrangement. The direct purchase was used
because given the multitude of cross-subsidizations and deals
that form a natural part of contract negotiations, the leasing cost
will be a poor proxy for the economic cost. Although the outright
purchase costs of MEA reusable equipment appeared high, the
annual equivalent cost was low as the equipment can be used for
many patients and over a prolonged period of time; therefore, the
cost assigned to each patient is more modest. Furthermore, MEA
utilizes relatively low-cost reusable equipment. In comparison,
although the cost per patient of the reusable equipment required
for TBALL was low, the cost of the disposable catheters was
relatively high, thus increasing the overall cost of TBALL.
Sensitivity analysis relaxing the assumptions made for the
base-case analysis resulted in the increase in the likelihood that
TBALL would be considered to be cost-effective to 20% when
the lifespan of the equipment was reduced to 5 years and 50
patients were treated annually (Table 5). Further one-way sensi-
tivity analyses based on the reduction of the costs TBALL equip-
ment increased the chance that TBALL would be cost-effective
(e.g., 40% when TBALL disposable catheters cost £50) indicat-
ing that the results were sensitive to the cost of equipment.
However, it is unlikely that the costs of equipment that would
change the conclusions drawn from the base-case are plausible
(Table 5). Results of sensitivity analysis based on the exclusion of
high-cost women (four from TBALL arm and one from MEA)
suggested that though the total difference in cost reduced to £94
from £181, they were not sensitive to the high service users,
therefore did not alter the conclusions drawn from the base-case
analysis.
Since this study is the ﬁrst head-to-head comparison of these
second-generation endometrial ablation techniques, there is need
for long-term follow-up to establish the failure rates and the
number of additional procedures. The results of the 12-month
follow-up questionnaire indicate that over time, 7 (2%) women
from the MEA group visited the gynecology department regard-
ing their periods, as did 10 (3%) in the TBALL group. Six women
in either arm had undergone hysterectomy at 12 months.
However, there is need to interpret these data with caution as this
information is only based on those that returned the 12-month
questionnaires. There were more data missing from women in
the TBALL group at 12 months (13% compared to 6% for
MEA) and this could be due to various reasons, such as women
who did not respond at 12 months having worse (or indeed
better) outcomes. It is also worth noting that the lack of statis-
tical differences may be due to the low statistical power in the
economic analysis rather than to a true lack of difference between
the groups as the sample size for the trial was determined for a
clinical end point and not on costs and QALYs.
Conclusion
This study indicates that for a 12-month time horizon, TBALL is
not likely to be considered cost-effective when compared with
MEA. This conclusion could change in light of further long-term
data on quality of life, failure rates, and costs. Longer-term
performance of both TBALL and MEA will be derived from
follow-up at 5 years.
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